Molecular Partners AG announced that the Board of Directors decided to appoint Patrick Amstutz, Ph.D., co-founder of the company, as Chief Executive Officer and to nominate him to become a member of the Board of Directors. When Christian Zahnd resigned as CEO of Molecular Partners in November 2016, the Board of Directors appointed Patrick Amstutz as acting CEO, and engaged in a process to find the best suitable internal or external candidate.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.315 CHF | +2.47% | -1.04% | -3.63% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.63% | 118M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- MOLN Stock
- News Molecular Partners AG
- Molecular Partners AG Announces Management Changes